IL-6 ASSOCIATED WITH GRADING OF CYTOKINE RELEASE SYNDROME AND MANAGEMENT TIME OF TOCILIZUMAB AFTER CAR-T CELL THERAPY
Author(s): ,
Chenggong Li
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
,
Heng Mei
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
,
Yu Hu
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
,
Tao Guo
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
,
Lin Liu
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
,
Lisha Ai
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
,
Huiwen Jiang
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
,
Lu Tang
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
Jun Deng
Affiliations:
Institute of Hematology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China;Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease,Wuhan,China
EHA Library. Mei H. Jun 15, 2019; 266839; PS1222
Dr. Heng Mei
Dr. Heng Mei
Contributions
Abstract

Abstract: PS1222

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Cytokine release syndrome(CRS) is the most prominent and serious toxicity of the CAR T cell therapy. It still lacks of the measurable indicator for CRS grading scales. The IL-6 receptor blocker, like tocilizumab, can effectively relieve CRS. However, the optimal management time of  tocilizumab is not yet determined, especially about prophylactic administration.

Aims
1.To evaluate the relationship between the peak level and time of serum cytokines and the CRS grading. 2.To assess the association between the level of serum cytokines and the efficacy of the CAR-T cell therapy. 3.To investigate the optimal management time of tocilizumab in the grading 2 CRS based on the level of serum IL-6.

Methods
34 patients were enrolled in the study, including 27 ALL patients and 4 DLBCL patients treated with anti-CD19 CAR-T cells and 3 MM patients with anti-BCMA and anti-CD38 CAR-T cells. All the patients were monitored with serum cytokines, including IL-6, IL-2, IL-10 and TNFα every day for one month after theinfusion of CAR-T cells and the toxicity was graded by CTCAE 5.0. We analyzed the relationships between the peak level and time of serum cytokines and the CRS grading. The association between the peak level of serum cytokines and the efficacy of the CAR-T cell therapy was also assessed. At the same time, we compared the optimal management time of tocilizumab in the grading 2 CRS based on the level of serum IL-6. Kruskal-Wallis tests or one-way ANOVA were used to compare the difference between two or more independent samples. P<0.05 was regarded significance.

Results
The peak level of IL-6 and IL-10 increased with the CRS grade(P<0.001) and there is no obvious association between the peak  level of IL-2(P=0.82) and TNFα(P=0.32) and CRS grade. The peak level of IL-6 and IL-10 of Grade 0 and Grade 0 was ≤ twice the upper  limit, Grade 2 ≤ 20 times the upper limit and Grade 3 and Grade 4 ≥ 200 times the upper limit. Only the occurrence time of the peak IL-6 raised with CRS grade(P=0.048).The occurrence time of the peak IL-6 of Grade 0 and Grade 0 was around the 6th day, Grade 2 and Grade 3 near the 10th day and Grade 4 the 12nd day. Except IL-2(P=0.005), no significant relationship between the the peak level of IL-6(P=0.972),  IL-10(P=0.995) and TNFα(P=0.420) and the efficacy of the CAR-T cell therapy. The peak level of IL-2 of no response was higher than partial or complete remission. 3/10 of patients with Grade 2 CRS were administered with tocilizumab(80mg) and one patient with lower peak level of IL-6 progressed with neurotoxicity. The other two patients with ≥ 30 times the upper limit of IL-6 were relieved. All the 9 patients with Grade 3 and Grade 4, whose peak level of IL-6 were ≥ 200 times the upper limit, were given with tocilizumab(160mg or 240mg) and under remission.

Conclusion
Our research demonstrates a positive correlation between thepeak level and time ofserum IL-6 and the CRS grade. The level of serum IL-6 is an important consideration for the administration of tocilizumab in the early stage of CRS, which can effectively avoid some adverse reactions such as CRES. (NCT02965092,  ChiCTR1800018143)

Session topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies